Your browser doesn't support javascript.
loading
Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia.
Aktas, Burak Yasin; Ata, Emine Büsra; Çesmeci, Engin; Çakir, Ibrahim Yahya; Coskunpinar, Muharrem; Tahillioglu, Yagmur; Güner, Gürkan; Güven, Deniz Can; Arik, Zafer; Kertmen, Neyran; Dizdar, Ömer; Yalçin, Suayib; Aksoy, Sercan.
Afiliación
  • Aktas BY; Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey.
  • Ata EB; Department of Medical Oncology, Guy's and Saint Thomas' NHS Trust, London SE1 9RT, UK.
  • Çesmeci E; Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey.
  • Çakir IY; Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey.
  • Coskunpinar M; Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey.
  • Tahillioglu Y; Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey.
  • Güner G; Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey.
  • Güven DC; Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey.
  • Arik Z; Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey.
  • Kertmen N; Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey.
  • Dizdar Ö; Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey.
  • Yalçin S; Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey.
  • Aksoy S; Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey.
Curr Oncol ; 30(11): 9689-9700, 2023 Nov 02.
Article en En | MEDLINE | ID: mdl-37999123
Anemia remains an essential concern affecting the quality of life and the survival of cancer patients. Although there are different approaches to treating anemia in cancer patients, the number of studies reporting the efficacy of iron replacement in cancer patients is limited. In this study, the efficacy and safety of iron carboxymaltose, a parenteral iron treatment option, in the treatment of anemia, were examined retrospectively. A total of 1102 adult patients who received IV ferric carboxymaltose treatment at Hacettepe Oncology Hospital between 2014 and 2020 were included. The mean hemoglobin change observed at the end of the 12th week was 1.8 g/dL, and the rate of patients with an increase in hemoglobin of 1 g/dL or more was 72.1%. It was observed that the treatment demonstrated effectiveness in patients receiving active cancer treatment in all tumor types. The treatment was generally safe, and no grade 3-5 side effects were observed in the patients included in the study. According to one of the most extensive series published in the literature, iron carboxymaltose is an efficient and safe alternative for cancer patients with iron-deficiency anemia.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anemia Ferropénica / Anemia / Neoplasias Límite: Adult / Humans Idioma: En Revista: Curr Oncol Año: 2023 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anemia Ferropénica / Anemia / Neoplasias Límite: Adult / Humans Idioma: En Revista: Curr Oncol Año: 2023 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Suiza